Загрузка...
The comparative effectiveness and cost-effectiveness of ranibizumab for neovascular macular degeneration revisited
BACKGROUND: To compare a near decade of follow-up, newer control cohort data, use of both the societal and third party insurer cost perspectives, and integration of unilateral/bilateral therapy on the comparative effectiveness and cost-effectiveness of intravitreal ranibizumab therapy for neovascula...
Сохранить в:
| Опубликовано в: : | Int J Retina Vitreous |
|---|---|
| Главные авторы: | , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
BioMed Central
2017
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5304393/ https://ncbi.nlm.nih.gov/pubmed/28289548 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40942-016-0058-3 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|